Abstract:Purpose: Colorectal cancer is the second most common cancer in women and the third most common in men worldwide. However, despite current progress, many patients with advanced and metastatic tumors still die from the malignancy. Refractory disease often relies on nicotinamide adenine dinucleotide (NAD)-dependent mechanisms. NAD metabolism and a stable NAD regeneration circuit are required to maintain tissue homeostasis and metabolism. However, high levels of NAD confer therapy resistance to tumors.Experimental Design: Ectopic overexpression of nicotinamide phosphoribosil transferase (NAMPT) and shRNAs in colorectal cancer cell lines, tumorigenic and stemness properties and transcription measurement in culture and in vivo Transcriptional analysis in public databases. Therapeutic approaches.Results: NAMPT, the rate-limiting enzyme responsible for the highest source of physiologic NAD biosynthesis, increases tumorigenic properties and induces cancer stem cell-like properties through pathways that control stem cell signaling, thus enriching the cancer-initiating cell (CIC) population. Furthermore, NAMPT expression correlated with high levels of CIC-like cells in colon tumors directly extracted from patients, and transcription meta-analysis revealed that NAMPT is also a key factor that induces cancer stem pathways in colorectal cancer tumors. This effect is mediated by PARP and SIRT1. In addition, we report a novel NAMPT-driven signature that stratifies prognosis from high to low expression groups. The NAMPT signature contained SIRT1 and PARP1 levels as well as other cancer stem cell-related genes. Finally, NAMPT inhibition increased the sensitivity to apoptosis in both NAMPT-expressing cells and tumorspheres.Conclusions: NAMPT represents a novel therapeutic target in colon cancer progression and relapse, particularly the CIC subset of human colon cancers. Clin Cancer Res; 24(5); 1202-15. ©2017 AACR.

NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

The Regulation of N6‐methyladenosine Modification in PD‐L1‐induced Anti‐tumor Immunity

The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor

NAD+ salvage governs mitochondrial metabolism invigorating NK cell anti‐tumor immunity

NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells

Immunosuppression reverse engineered from cancer: Reducing nicotinamide adenine dinucleotide (NAD) impairs effector T cell function through glycolysis

ALDH1A1 promotes immune escape of tumor cells through ZBTB7B-glycolysis pathway

NAD + depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition

PD-1 and its ligands are important immune checkpoints in cancer

NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP

METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer

Cohesin mutation sensitizes cancer cells to anti-PD-1 therapy through endogenous retrovirus-mediated PD-L1 upregulation

Targeting NAD metabolism regulates extracellular adenosine levels to improve the cytotoxicity of CD8+ effector T cells in the tumor microenvironment of gastric cancer

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer

Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment

Targeting NAD+ Metabolism: Preclinical Insights into Potential Cancer Therapy Strategies

Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade

N-linked glycosylation of PD-L1/PD-1: an emerging target for cancer diagnosis and treatment

NAD + Supplementation Limits Triple-Negative Breast Cancer Metastasis Via SIRT1-P66Shc Signaling